Lonza has launched a new version of its gene expression system that cuts weeks off the cell line development and construction process.
‘Xceed’ is the latest version of the glutamine synthetase (GS) expression system – which is used to produce 13 approved drugs and by companies like Genentech , Roche, Medimmune and Elusys – and is based on the new CHOK1SV GS knock-out host cell line Lonza developed.
The firm claims that - compared with the old CHO1SV-based system – Xceed’s new line can to reduce development timelines by 6 weeks, which it believes can be a real advantage to developers.
“Successful cell line construction, selection and development are on the critical path to achieving first in human studies. By shortening the development timeline by up to 6 weeks, customers gain a significant advantage in their product development lifecycle.”